IVAN PECIN

doc.dr.sc.Ivan Pećin dr.med.

IVAN PECIN
doc.dr.sc.

born in 1978.g. in Zagreb.

PERSONAL DATA, EDUCATION AND EMPLOYMENT

Rođen je 1978. godine u Zagrebu, osnovnu i srednju školu (prirodoslovno-matematičku gimnaziju) završio je u Samoboru. Nakon završenog Medicinskog fakulteta Sveučilišta u Zagrebu započinje specijalizaciju iz Interne medicine pri KBC Zagreb te polaže specijalistički ispit 2010. godine. 2013. godine polaže subspecijalistički ispit iz endokrinologije i dijabetologije. 2010.- postaje magistar prirodnih znanosti iz polja imunobiologije pri Prirodoslovno-matematičkom fakultetu Sveučilišta u Zagrebu. Po završetku magisterija upisuje doktorski studij iz biomedicine i zdravstva pri Medicinskom fakultetu Sveučilišta u Zagrebu. 2015. stječe diplomu doktora znanosti. Aktivno je uključen u nastavu pri medicinskom fakultetu na hrvatskom i engleskom jeziku. 2017. godine postaje docent pri katedri za internu medicinu medicinskog fakulteta sveučilišta u Zagrebu. Pomoćnik je voditelja doktorskog studija medicinskog fakulteta Sveučilišta u Zagrebu, organizator „Dana doktorata“. Od usavršavanja u vanjskim centrima izvrsnosti za spomenuti je usavršavanje pri Centru za kardiovaskularnu genetiku UCL (University college London, UK) na području genetike složenih dislipidemija – porodična hiperkolesterolemija.

Po položenom specijalističkom ispitu zaposlen je u Kliničkom bolničkom centru Zagreb, Klinici za unutrašnje bolesti, Zavodu za bolesti metabolizma. Uže područje interesa je preventivna kardiologija – dislipidemije, dijabetes, arterijska hipertenzija i rijetke bolesti metabolizma. Radi i u Ambulanti za poremećaj lipida koja djeluje pri Referentnom centru Ministarstva zdravstva za rijetke i metaboličke bolesti Republike Hrvatske.
Aktivan je član i nekoliko nacionalnih i međunarodnih društava. Podpredsjednik je Hrvatskog društva za aterosklerozu HLZ i Hrvatskog društva za rijetke bolesti. Rizničar je Hrvatskog društva za hipertenziju HLZ. Član je Hrvatskog društva za endokrinologiju i dijabetologiju, Europskog društva za aterosklerozu, Europskog društva za hipertenziju.

Organizator je niza domaćih ali i međunarodnih skupova od kojih je za izdvojiti Hrvatski kongres o aterosklerozi, Hrvatski kongres o rijetkim bolestima, Hrvatski kongres o hipertezniji, Dubrovačka škola lipida, simpozij HAZU na temu prevencija ateroskleroze, aktivni je sudionik projekata proizašlih iz rada navedenih stručnih društava. Iza sebe ima niz pozvanih predavanja na navedenim skupovima.
Trenutno je suvoditelj projekta za rani probir i otkrivanje bolesnika sa porodičnom hiperkolesterolemijom.

PUBLICATIONS:
Total number of citations: 7727

  • 1: Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM,Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW,Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174.
  • 2: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017 Dec 16;390(10113):2627-2642. doi:10.1016/S0140-6736(17)32129-3.
  • 3: NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature. 2019 May;569(7755):260-264. doi: 10.1038/s41586-019-1171-x.
  • 4: Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the
    ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Erratum in: Lancet Diabetes Endocrinol. 2019 Jul 8;: Erratum in: Lancet Diabetes Endocrinol. 2019 Sep;7(9):e21.
  • 5: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet. 2017 Jan 7;389(10064):37-55. doi: 10.1016/S0140-6736(16)31919-5. Epub 2016 Nov 16. Erratum in: Lancet. 2020 Sep 26;396(10255):886.
  • 6: Pećin I, Reiner Ž. Alirocumab: targeting PCSK9 to treat hypercholesterolemia. Drugs Today (Barc). 2015 Dec;51(12):681-7. doi: 10.1358/dot.2015.51.12.2435830.
  • 7: Pećin I, Reiner Ž. Novel Experimental Agents for the Treatment of Hypercholesterolemia. J Exp Pharmacol. 2021 Feb 11;13:91-100. doi: 10.2147/JEP.S267376.
  • 8: Šimić I, Pećin I, Muačević-Katanec D, Šućur N, Reiner Ž. Odgovor autora [Author reply]. Lijec Vjesn. 2014 Sep-Oct;136(9-10):302-3. Croatian.
  • 9: Sahebkar A, Pećin I, Tedeschi-Reiner E, Derosa G, Maffioli P, Reiner Ž. Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. Int J Cardiol. 2016 Jun 1;212:160-8. doi: 10.1016/j.ijcard.2016.03.010.
  • 10: Pećin I, Hartgers ML, Hovingh GK, Dent R, Reiner Ž. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol. 2017 Sep;24(13):1383-1401. doi: 10.1177/2047487317717346. Epub 2017 Jun 23.
  • 11: Vodanović M, Lucijanić M, Zupančić Šalek S, Pećin I. Prevalence of and risk factors for urolithiasis in Croatian patients with hemophilia. Int J Hematol. 2021 May;113(5):656-661. doi: 10.1007/s12185-020-03064-9.
  • 12: Merkler A, Sertić J, Bazina Martinović A, Križ T, Miličić I, Šimić M, Caban D, Ljubić H, Markeljević J, Šimičević L, Kaštelan S, Pećin I, Reiner Ž. Haptoglobin genotype 2-2 associated with atherosclerosis in patients with ischemic stroke. Gene. 2020 Aug 20;752:144786. doi: 10.1016/j.gene.2020.144786.
  • 13: Adamec I, Reiner Ž, Pećin I, Šućur N, Godan Hauptman A, Barun B, Gabelić T, Habek M. Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Oct;45:102381. doi: 10.1016/j.msard.2020.102381.
  • 14: Pećin I, Reiner Ž. Metabolic Syndrome, Morbidity and Mortlity – in the Era of COVID-19 Pandemic. Psychiatr Danub. 2021 Spring-Summer;33(Suppl 4):441-444.
  • 15: Merkler M, Pećin I, Simić I, Muacević-Katanec D, Sućur N, Reiner Z. Fabryjeva bolest- smjernice za dijagnozu i lijecenje odraslih bolesnika [Fabry disease–guidelines for diagnosis and management of adult patients]. Lijec Vjesn. 2014 May-Jun;136(5-6):133-5. Croatian.
  • 16: Kuzmanić D, Laganović M, Dika Z, Kos J, Pećin I. Antihipertenzivni lijekovi i rizik od novonastale sećerne bolesti [Antihypertensive agents and the risk of new onset diabetes mellitus]. Lijec Vjesn. 2006 Nov-Dec;128(11-12):336-41.
    17: Pećin I, Leskovar D, Šabić M, Perica D, Šućur N, Godan Hauptman A, Merćep I, Borovečki F, Premužić V, Jelaković B, Reiner Ž. Prophylactic therapeutic plasma exchange in pregnant woman with Familial Chylomicronemia Syndrome – A case report. Transfus Apher Sci. 2021 Dec 15:103346. doi: 10.1016/j.transci.2021.103346.
  • 18: Pećin I, Whittall R, Futema M, Sertić J, Reiner Z, Leigh SE, Humphries SE. Mutation detection in Croatian patients with familial hypercholesterolemia. Ann Hum Genet. 2013 Jan;77(1):22-30. doi: 10.1111/j.1469-1809.2012.00735.x.
  • 19: NCD Risk Factor Collaboration (NCD-RisC). A century of trends in adult human height. Elife. 2016 Jul 26;5:e13410. doi: 10.7554/eLife.13410. PMID: 27458798;
  • 20: Merkler M, Simić I, Pećin I, Muacević-Katanec D, Sucur N, Reiner Z. Gaucherova bolest–smjernice za dijagnozu i lijecenje odraslih bolesnika [Gaucher disease–guidelines for diagnosis and management of adult patients]. Lijec Vjesn. 2014 May-Jun;136(5-6):130-3. Croatian.
  • 21: Muačević-Kataneć D, Pećin I, Šimić I, Fumić K, Potočki K, Šućur N, Reiner Ž; Croation Society for Rare Diseases, Croatian Medical Association. SMJERNICE ZA LIJEČENJE MUKOPOLISAHARIDOZE (MPS) VI U ODRASLIH BOLESNIKA [Management of mucopolysaccharidosis type VI in adults]. Lijec Vjesn. 2015 Jul- Aug;137(7-8):213-5.
  • 22: Češka R, Paragh G, Reiner Ž, Banach M, Tokgözoğlu L, Susekov AV, Rašlová K, Freiberger T, Vohnout B, Rynkiewicz A, Goudev A, Dan GA, Gaiţă D, Pojskić B, Pećin I, Kayıkçıoğlu M, Mitchenko O, Ezhov MV, Latkovskis G, Petrulionienė Ž, Fras Z, Tasić N, Mirrakhimov EM, Murataliev T, Shek AB, Tuka V, Tselepis AD, Moubarak EM, Rasadi KA. ScreenPro FH – Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Rationale and Design. Vnitr Lek. 2017 Winter;63(1):43-48. English. PMID: 28225290.
  • 23: Češka R, Freiberger T, Susekov AV, Paragh G, Reiner Ž, Tokgözoğlu L, Rašlová K, Banach M, Vohnout B, Rynkiewicz A, Goudev A, Dan GA, Gaiţă D, Pojskić B, Pećin I, Kayıkçıoğlu M, Mitchenko O, Ezhov MV, Latkovskis G, Petrulionienė Ž, Fras Z, Tasić N, Mirrakhimov EM, Murataliev T, Shek AB, Tuka V, Tselepis AD, Moubarak EM, Al Rasadi K. ScreenPro FH – Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe: Basic Epidemiology. Vnitr Lek. 2017 Winter;63(1):25-30. English. PMID: 28225288.
  • 24: Pećin I, Cvorišćec D, Miletić-Medved M, Dika Z, Cvitković A, Vitale K, Leko N, Novaković D, Sertić J, Kos J, Jelaković B. Angiotensin-converting enzyme gene polymorphism and N-Acetyl-β-D-glucosaminidase excretion in endemic nephropathy.Nephron Clin Pract. 2011;119(2):c105-12. doi: 10.1159/000327528.
  • 25: Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care. 2021 May;44(5):1219-1227.doi: 10.2337/dc20-2842.
  • 26: Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi:10.1016/j.jacc.2021.04.102.
  • 27: Ivković V, Jelaković M, Laganović M, Pećin I, Vrdoljak A, Karanović S, Fuček M, Božina T, Kos J, Željković Vrkić T, Premužić V, Živko M, Jelaković B. Adiponectin is not associated with blood pressure in normotensives and untreated hypertensives with normal kidney function. Medicine (Baltimore). 2014 Dec;93(28):e250. doi: 10.1097/MD.0000000000000250.
  • 28: Pećin I, Muačević-Katanec D, Šimić I, Fumić K, Potočki K, Šućur N, Reiner Ž; Croatian Society for Rare Diseases, Croatian Medical Association. POMPEOVA BOLEST – SMJERNICE ZA DIJAGNOZU I LIJEČENJE ODRASLIH BOLESNIKA [POMPE DISEASE – GUIDELINES FOR DIAGNOSIS AND MANAGEMENT OF ADULT PATIENTS]. Lijec Vjesn. 2015 Jul-Aug;137(7-8):216-8.
  • 29: Laganović M, Kuzmanić D, Zeljković-Vrkić T, Pećin I, Dika Z, Jelaković B. Kidney volume and albuminuria as markers of birth weight-blood pressure relationship in essential hypertension. Kidney Blood Press Res. 2009;32(6):399-404. doi: 10.1159/000260041.
  • 30: Pećin I, Sućur N, Reiner Z. Porodicna hiperkolesterolemija – mislimo li dovoljno o ovoj teskoj bolesti? [Familial hypercholesterolemia – do we think enough about this severe disease?]. Lijec Vjesn. 2013 May-Jun;135(5-6):145-9.
  • 31: EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021 Nov 6;398(10312):1713-1725. doi: 10.1016/S0140-6736(21)01122-3.
  • 32: NCD Risk Factor Collaboration (NCD-RisC). Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. Elife. 2021 Mar 9;10:e60060. doi: 10.7554/eLife.60060.
  • 33: Pećin I, Samovojska R, Heinrich B, Zeljković-Vrkić T, Laganović M, Jelaković B. Hypertension, overweight and obesity in adolescents: the CRO-KOP study. Coll Antropol. 2013 Sep;37(3):761-4. PMID: 24308213.
  • 34: NCD Risk Factor Collaboration (NCD-RisC). Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. Int J Epidemiol. 2018 Jun 1;47(3):872-883i. doi:10.1093/ije/dyy016.
  • 35: Bozina T, Simić I, Lovrić J, Pećin I, Jelaković B, Sertić J, Reiner Z. Effects of lipoprotein lipase and peroxisome proliferator-activated receptor- gamma gene variants on metabolic syndrome traits. Coll Antropol. 2013 Sep;37(3):801-8.
  • 36: Petrovic I, Pecin I, Prutki M, Augustin G, Nedic A, Gojevic A, Potocki K, Reiner Z. Thigh abscess as an extension of psoas abscess: the first manifestation of perforated appendiceal adenocarcinoma: case report. Wien Klin Wochenschr. 2015 Aug;127(15-16):645-8. doi: 10.1007/s00508-014-0651-0.
  • 37: Simić I, Pećin I, Tedeschi-Reiner E, Zrinsćak O, Sućur N, Reiner Z. Risk factors for microvascular atherosclerotic changes in patients with type 2 diabetes mellitus. Coll Antropol. 2013 Sep;37(3):783-7. PMID: 24308217.
  • 38: Pećin I, Milicić D, Jurin H, Reiner Z. A pilot Croatian survey of risk factor (CRO-SURF) management in patients with cardiovascular disease. Coll Antropol. 2012 Jun;36(2):369-73.
  • 39: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-980. doi: 10.1016/S0140-6736(21)01330-1.
  • 40: Jelaković B, Zeljković-Vrkić T, Pećin I, Dika Z, Jovanović A, Podobnik D, Smuc T, Gamberger D, Katić K, Kasner M, Kuzmanić D; EH-UH istrazivacke skupine. Arterijska hipertenzija u Hrvatskoj. Rezultati EH-UH studije [Arterial hypertension in Croatia. Results of EH-UH study]. Acta Med Croatica. 2007 Jun;61(3):287-92.)
  • 41: Jelaković B, Kuzmanić D, Milicić D, Reiner Z, Aganović I, Basić-Jukić N, Bozikov J, Cikes M, Dika Z, Delmis J, Galesić K, Hrabak-Zerjavić V, Ivanusa M, Juresa V, Katić M, Kern J, Kes P, Laganović M, Pavlović D, Pećin I, Pocanić D, Racki S, Sabljar-Matovinović M, Sonicki Z, Vrcić-Keglević M, Vuletić S, Zaputović L; Croatian Working Group for Hypertension. Smjernice za dijagnosticiranje i lijecenje arterijske hipertenzije. Prakticne preporuke hrvatske radne skupine i osvrt na smjernice ESH/ESC 2007 [Guidelines for diagnostics and treatment of arterial hypertension. Practical recommendations of the Croatian Working Group for Hypertension. Consideration on the ESH-ESC 2007 guidelines]. Lijec Vjesn. 2008 May-Jun;130(5-6):115-32.
  • 42: Jelaković B, Dika Z, Kos J, Pećin I, Laganović M, Jovanović A, Smuc T, Gamberger D, Kuzmanić D. Lijecenje i kontrola arterijske hipertenzije u hrvatskoj. BEL-AH istrazivanje [Treatment and control of hypertension in Croatia. The BEL-AH study]. Lijec Vjesn. 2006 Nov-Dec;128(11-12):329-33.
  • 43: Jovanović A, Laganović M, Dika Z, Kos J, Pećin I. Utjecaj abdominalne debljine na vrijednosti tlaka u bolesnika s esencijalnom hipertenzijom [Influence of visceral obesity on blood pressure values in patients with essential hypertension]. Lijec Vjesn. 2006 Nov-Dec;128(11-12):393-5.